Merck (MRK +0.5%) gives a ray hope to its dwindling pipeline, after saying that Phase 2b studies of MK-3102, its investigational once-weekly treatment for Type 2 diabetes , significantly lowered blood sugar when compared with a placebo. The pharmaceutical giant presented the data at the annual meeting of the European Association for the Study of Diabetes in Berlin, noting the results were very encouraging and it plans to begin Phase 3 studies very soon.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Feb 24, 2015)
at MarketWatch.com (Feb 23, 2015)
at CNBC.com (Feb 4, 2015)
at MarketWatch.com (Feb 2, 2015)
at Nasdaq.com (Jan 27, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs